FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
about
Current therapeutic strategies for advanced pancreatic cancer: A review for cliniciansA phase II study of sorafenib, oxaliplatin, and 2 days of high-dose capecitabine in advanced pancreas cancer.Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort.What treatment in 2017 for inoperable pancreatic cancers?Bioinformatory-assisted analysis of next-generation sequencing data for precision medicine in pancreatic cancer.Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies.
P2860
FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
FOLFOX as second-line chemothe ...... c cancer from the FIRGEM study
@ast
FOLFOX as second-line chemothe ...... c cancer from the FIRGEM study
@en
type
label
FOLFOX as second-line chemothe ...... c cancer from the FIRGEM study
@ast
FOLFOX as second-line chemothe ...... c cancer from the FIRGEM study
@en
prefLabel
FOLFOX as second-line chemothe ...... c cancer from the FIRGEM study
@ast
FOLFOX as second-line chemothe ...... c cancer from the FIRGEM study
@en
P2093
P2860
P356
P1433
P1476
FOLFOX as second-line chemothe ...... c cancer from the FIRGEM study
@en
P2093
Anne Thirot-Bidault
Anne-Claire Dupont-Gossart
Aziz Zaanan
Daniella Fanica
Fanny Joubert
Isabelle Trouilloud
Mélanie Gauthier
Pascal Artru
Theofano Markoutsaki
Thierry Lecomte
P2860
P2888
P356
10.1186/1471-2407-14-441
P407
P50
P577
2014-06-14T00:00:00Z
P5875
P6179
1018864975